TRC105

Phase 3Biologic

TTracon Pharmaceuticals Inc.

TRC105 is one of 260 biologic programs targeting Choriocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

259

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChoriocarcinomaActive, not recruiting

Lung CancerActive, not recruiting

AngiosarcomaActive, not recruiting

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

GlioblastomaActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

ChoriocarcinomaPhase 2

Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

AngiosarcomaPhase 3

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

TRC105

TTracon Pharmaceuticals Inc.

Phase 3

2 2

Tykerb

GSK

Preclinical

80 3

Halaven

Eisai

Preclinical

38 4

Avastin

Prolia

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

MS Contin

Merck & Co.

Preclinical

2 8

Voltaren

Novartis

Preclinical

1 9

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 10

Effexor

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma2 trials

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

Completed·TTracon Pharmaceuticals Inc.·Phase 2·NCT01564914·22 enrolled

TRC105 for Recurrent Glioblastoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01778530·2 enrolled

Prostate Cancer2 trials

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Completed·—·Phase 2·NCT03418324·11 enrolled

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01090765·21 enrolled

Breast Cancer2 trials

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Completed·TTracon Pharmaceuticals Inc.·Phase 1/2·NCT01326481·19 enrolled

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT02520063·15 enrolled

Choriocarcinoma1 trial

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Completed·TTracon Pharmaceuticals Inc.·Phase 2·NCT02396511·2 enrolled

Urothelial Carcinoma1 trial

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01328574·13 enrolled

10 more indications

Angiosarcoma1 trial

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

Completed·TTracon Pharmaceuticals Inc.·Phase 3·NCT02979899·128 enrolled

Solid Cancer1 trial

Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

Completed·TTracon Pharmaceuticals Inc.·Phase 1·NCT00582985·51 enrolled

Renal Cell Carcinoma1 trial

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Terminated·TTracon Pharmaceuticals Inc.·Phase 1/2·NCT01806064·173 enrolled

Advanced Solid Tumors1 trial

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Completed·TTracon Pharmaceuticals Inc.·Phase 1·NCT01332721·38 enrolled

Soft Tissue Sarcoma1 trial

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Completed·TTracon Pharmaceuticals Inc.·Phase 1/2·NCT01975519·111 enrolled

Trial1 trial

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No longer available·TTracon Pharmaceuticals Inc.··NCT02354612

Lung Cancer1 trial

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Completed·UUniversity of Alabama at Birmingham·Phase 1·NCT02429843·16 enrolled

Liver Cancer1 trial

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01375569·11 enrolled

Bevacizumab1 trial

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Terminated·TTracon Pharmaceuticals Inc.·Phase 2·NCT02664961·3 enrolled

Carboplatin1 trial

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

Completed·TTracon Pharmaceuticals Inc.·Phase 1·NCT03780010·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for TRC105. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRC105 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRC105. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tracon Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: TTracon Pharmaceuticals Inc.

TRC105

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma2 trials

Prostate Cancer2 trials

Breast Cancer2 trials

Choriocarcinoma1 trial

Urothelial Carcinoma1 trial

Angiosarcoma1 trial

Solid Cancer1 trial

Renal Cell Carcinoma1 trial

Advanced Solid Tumors1 trial

Soft Tissue Sarcoma1 trial

Trial1 trial

Lung Cancer1 trial

Liver Cancer1 trial

Bevacizumab1 trial

Carboplatin1 trial

References

Drug Info

Quick Facts

Related News